{"nct_id":"NCT01613118","title":"Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis","status":"COMPLETED","status_verified_date":"2025-04","start_date":"2014-03","start_date_type":"ACTUAL","primary_completion_date":"2016-06","primary_completion_date_type":"ACTUAL","completion_date":"2024-03-25","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["TVTX"]}